These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37863349)

  • 1. Increased peripheral of brain-derived neurotrophic factor levels in phenylketonuric patients treated with l-carnitine.
    Faverzani JL; Guerreiro G; Hammerschmidt TG; Lopes FF; Coelho DM; Sitta A; Mescka CP; Deon M; Wajner M; Vargas CR
    Arch Biochem Biophys; 2023 Nov; 749():109792. PubMed ID: 37863349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cytokine levels induced by high phenylalanine concentrations in late diagnosis PKU patients compared to early diagnosis: Anti-inflammatory effect of L-carnitine.
    Faverzani JL; Hammerschmidt TG; Mescka CP; Guerreiro G; Lopes FF; Delgado CA; de Moura Coelho D; Sitta A; Deon M; Wajner M; Vargas CR
    Cell Biochem Funct; 2023 Jun; 41(4):490-500. PubMed ID: 37170672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-carnitine protects DNA oxidative damage induced by phenylalanine and its keto acid derivatives in neural cells: a possible pathomechanism and adjuvant therapy for brain injury in phenylketonuria.
    Faverzani JL; Steinmetz A; Deon M; Marchetti DP; Guerreiro G; Sitta A; de Moura Coelho D; Lopes FF; Nascimento LVM; Steffens L; Henn JG; Ferro MB; Brito VB; Wajner M; Moura DJ; Vargas CR
    Metab Brain Dis; 2021 Oct; 36(7):1957-1968. PubMed ID: 34216350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that L-carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients.
    Sitta A; Vanzin CS; Biancini GB; Manfredini V; de Oliveira AB; Wayhs CA; Ribas GO; Giugliani L; Schwartz IV; Bohrer D; Garcia SC; Wajner M; Vargas CR
    Cell Mol Neurobiol; 2011 Apr; 31(3):429-36. PubMed ID: 21191647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-carnitine blood levels and oxidative stress in treated phenylketonuric patients.
    Sitta A; Barschak AG; Deon M; de Mari JF; Barden AT; Vanzin CS; Biancini GB; Schwartz IV; Wajner M; Vargas CR
    Cell Mol Neurobiol; 2009 Mar; 29(2):211-8. PubMed ID: 18814025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of L-carnitine on Phenylalanine-induced DNA damage.
    Deon M; Landgraf SS; Lamberty JF; Moura DJ; Saffi J; Wajner M; Vargas CR
    Metab Brain Dis; 2015 Aug; 30(4):925-33. PubMed ID: 25600689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profile and peripheral markers of neurodegeneration in patients with Niemann-Pick type C: Decrease in Plasminogen Activator Inhibitor type 1 and Platelet-Derived Growth Factor type AA.
    Hammerschmidt TG; Encarnação M; Lamberty Faverzani J; de Fátima Lopes F; Poswar de Oliveira F; Fischinger Moura de Sousa C; Ribeiro I; Alves S; Giugliani R; Regla Vargas C
    Arch Biochem Biophys; 2023 Feb; 735():109510. PubMed ID: 36608914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria.
    Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C
    Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term dietary intervention with low Phe and/or a specific nutrient combination improve certain aspects of brain functioning in phenylketonuria (PKU).
    Bruinenberg VM; van Vliet D; van der Goot E; Counotte DS; Kuhn M; van Spronsen FJ; van der Zee EA
    PLoS One; 2019; 14(3):e0213391. PubMed ID: 30875376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that DNA damage is associated to phenylalanine blood levels in leukocytes from phenylketonuric patients.
    Sitta A; Manfredini V; Biasi L; Treméa R; Schwartz IV; Wajner M; Vargas CR
    Mutat Res; 2009; 679(1-2):13-6. PubMed ID: 19665577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.
    Zori R; Thomas JA; Shur N; Rizzo WB; Decker C; Rosen O; Li M; Schweighardt B; Larimore K; Longo N
    Mol Genet Metab; 2018 Nov; 125(3):217-227. PubMed ID: 30146451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics.
    Levy H; Lamppu D; Anastosoaie V; Baker JL; DiBona K; Hawthorne S; Lindenberger J; Kinch D; Seymour A; McIlduff M; Watling S; Vockley J
    Mol Genet Metab; 2020 Mar; 129(3):177-185. PubMed ID: 31883647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of phenylalanine on cognitive, cerebral, and neurometabolic parameters in adult patients with phenylketonuria (the PICO study): a randomized, placebo-controlled, crossover, noninferiority trial.
    Trepp R; Muri R; Abgottspon S; Bosanska L; Hochuli M; Slotboom J; Rummel C; Kreis R; Everts R
    Trials; 2020 Feb; 21(1):178. PubMed ID: 32054509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria.
    Ney DM; Hull AK; van Calcar SC; Liu X; Etzel MR
    J Nutr; 2008 Feb; 138(2):316-22. PubMed ID: 18203898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carnitine status in early-treated children, adolescents and young adults with phenylketonuria on low phenylalanine diets.
    Weigel C; Kiener C; Meier N; Schmid P; Rauh M; Rascher W; Knerr I
    Ann Nutr Metab; 2008; 53(2):91-5. PubMed ID: 18946205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.
    Vernon HJ; Koerner CB; Johnson MR; Bergner A; Hamosh A
    Mol Genet Metab; 2010 Jul; 100(3):229-33. PubMed ID: 20418136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study.
    Schindeler S; Ghosh-Jerath S; Thompson S; Rocca A; Joy P; Kemp A; Rae C; Green K; Wilcken B; Christodoulou J
    Mol Genet Metab; 2007 May; 91(1):48-54. PubMed ID: 17368065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of phenylalanine on the survival and neurite outgrowth of rat cortical neurons in primary cultures: possible involvement of brain-derived neurotrophic factor.
    Li D; Gu X; Lu L; Liang L
    Mol Cell Biochem; 2010 Jun; 339(1-2):1-7. PubMed ID: 20101519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomic Markers of Essential Fatty Acids, Carnitine, and Cholesterol Metabolism in Adults and Adolescents with Phenylketonuria.
    Stroup BM; Nair N; Murali SG; Broniowska K; Rohr F; Levy HL; Ney DM
    J Nutr; 2018 Feb; 148(2):194-201. PubMed ID: 29490096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H;
    Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.